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Abstract 
The Fontan operation creates a circulation characterized by elevated central venous pressure 
and low cardiac output. Over time, these characteristics result in a predictable and persistent 
decline in exercise performance that is associated with an increase in morbidity and mortality. A 
medical therapy that targets the abnormalities of the Fontan circulation might, therefore, be 
associated with improved outcomes. Udenafil, a phosphodiesterase type 5 inhibitor, has 
undergone phase I/II testing in adolescents who have had the Fontan operation and has been 
shown to be safe and well tolerated in the short-term. However, there are no data regarding the 
long-term efficacy of udenafil in this population.  The Fontan Udenafil Exercise Longitudinal 
(FUEL) Trial is a randomized, double blind, placebo controlled phase III clinical trial being 
conducted by the Pediatric Heart Network in collaboration with Mezzion Pharma Co., Ltd.  This 
trial is designed to test the hypothesis that treatment with udenafil will lead to an improvement in 
exercise capacity in adolescents who have undergone the Fontan operation. A safety extension 
trial, the FUEL Open-Label Extension Trial (FUEL OLE), offers the opportunity for all FUEL 
subjects to obtain open-label udenafil for an additional 12 months following completion of FUEL, 
and evaluates the long-term safety and tolerability of this medication.  This manuscript 
describes the rationale and study design for FUEL and FUEL OLE.  Together, these trials 
provide an opportunity to better understand the role of medical management in the care of those 
who have undergone the Fontan operation. 
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The Fontan circulation 
When first described in 1971, the Fontan operation ushered in a new paradigm in the care of 
children born with the varied forms of complex congenital heart disease (CHD) characterized by 
a single effective pumping chamber(1,2).  This procedure, which creates a total cavopulmonary 
connection, separates the systemic and pulmonary circuits and reduces both hypoxemia and 
ventricular volume overload.  However, while life-saving or life-prolonging for many, the 
circulation created by the Fontan operation is not normal.  After the Fontan, there is no 
ventricular pump to propel blood through the pulmonary arteries.  Instead, blood returns to the 
lungs via passive flow from the systemic veins and is dependent on low pulmonary vascular 
resistance and optimal diastolic ventricular function.  This creates a circulation characterized by 
elevated central venous pressure and chronically low cardiac output.  Over time, these inherent 
characteristics of Fontan physiology result in a predictable, persistent deterioration of 
cardiovascular efficiency marked by a progressive decline in exercise performance as well as 
impaired ventricular and vascular function(3-8).  Medical therapies that can favorably alter the 
deficiencies of the Fontan circulation might help to slow the decline associated with Fontan 
physiology and lead to improved outcomes over a lifetime(9). 
 
Exercise performance in the Fontan circulation 
The Fontan circulation significantly limits the ability to increase cardiac output in the setting of 
increased metabolic demand(10).  In a two-ventricle circulation, the sub-pulmonary ventricle 
facilitates the increased blood flow and augmented preload required to increase cardiac output 
during exercise(11,12).  In the single ventricle circulation, the central venous pressure provides 
the driving force that propels blood through the pulmonary vasculature.  Central venous 
pressure can rise during periods of increased demand, but the increase in pressure is 
substantially less than that which can be generated by a sub-pulmonary ventricle(13).  As a 
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result of limited trans-pulmonary blood flow, ventricular preload and cardiac output are likewise 
limited(14).   
 
These limitations of the Fontan physiology are demonstrated in evaluations of exercise 
performance.  While many patients with CHD have lower maximal exercise capacity (maximal 
oxygen consumption; VO2 max) than age- and gender-matched peers, those with the Fontan 
physiology have among the lowest(15,16).  In the Pediatric Heart Network’s (PHN) cross-
sectional study of exercise performance in 411 children following Fontan, VO2 max was 65% of 
predicted for age and gender at 12 years of age and decreased progressively in the older 
cohorts(3,4).  In multiple subsequent longitudinal studies, the progressive decline in exercise 
capacity has been confirmed, although the slope of the decline has varied by study, ranging 
from 0.8-2.6% of the predicted VO2 max per year(3,5-7).   
 
The quantification of exercise capacity is not only a useful descriptor of functional capacity, it is 
also a reliable predictor of morbidity and mortality in those with congenital or acquired heart 
disease.  In studies of young adults with CHD, a VO2 max of approximately 45-50% of predicted 
for age and gender (an absolute VO2 max of 18 to 20 ml/kg/min in young adults) appears to be 
the threshold value for an increased risk of symptomatic heart failure and death.  This finding is 
consistent across many diagnostic categories of CHD(17-20). In one study of 321 subjects with 
Fontan physiology, the maximal VO2 was 52% of predicted at a mean age of 21 years.  During a 
median follow up time of 21 months, 41% of patients required hospitalization for heart failure 
and 9% either died or underwent heart transplantation(19).  
 
Pulmonary vasodilation and the Fontan circulation 
In the absence of a sub-pulmonary ventricle, the importance of pulmonary vascular resistance 
(PVR) as a determinant of cardiac preload and output is magnified(14).  Any small elevation in 
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PVR necessitates an increase in central venous pressure to maintain cardiac output, and/or 
results in a decrease in cardiac output for any given central venous pressure.  Likewise, any 
small decrease in PVR allows for a decrease in central venous pressure for any given cardiac 
output, and/or an increase in cardiac output for any given central venous pressure.  Additional 
evidence suggests that even in the setting of a normal resting PVR, the typical decrease in PVR 
that occurs with exercise in two-ventricle circulations – facilitating substantial augmentation in 
cardiac output – does not occur during exercise in those with the Fontan circulation(21,22).  
Given the importance of PVR in the Fontan circulation, pulmonary vasodilators make intuitive 
sense as a class of drug that might be successful at improving the Fontan physiology.   
 
Over the last decade, numerous studies have evaluated the acute, short-term, and medium-
term impact of pulmonary vasodilators on Fontan physiology(23-31).  While different classes of 
medications have been evaluated, phosphodiesterase-5 (PDE-5) inhibitors have the longest 
track record of use in pediatrics and have an excellent safety profile.  PDE-5 inhibitors have 
been used for more than a decade as the first-line therapy for children with pulmonary arterial 
hypertension and have been associated with increased exercise performance as well as 
increased measures of quality of life in that group(32-35).   
 
In children with Fontan physiology, there have been a number of acute and short-term efficacy 
studies of PDE-5 inhibitors, some that have suggested an improvement in exercise performance 
and others that have been equivocal(24,25,27,36).  In the earliest publication, sildenafil was 
shown to improve exercise capacity and cardiac output after a single dose(36).  In the largest 
and longest evaluation of sildenafil (6 weeks of therapy, 28 subjects), the authors found an 
improvement in submaximal exercise in those with heart failure (defined as a serum brain-type 
natriuretic peptide >100 pg/ml) but no improvement in VO2 max.  Interestingly, the authors also 
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found an improvement in ventricular performance as quantified by the myocardial performance 
index(26,27). 
 
Study design and methods 
Study overview 
The Fontan Udenafil Exercise Longitudinal (FUEL) trial, a unique collaboration between the 
PHN and industry, is designed to test the hypothesis that treatment with udenafil will lead to an 
improvement in exercise capacity, as measured by VO2 max, in a cohort of adolescents who 
have undergone the Fontan operation.  This trial has an enrollment goal of 400 adolescents who 
will be randomly assigned to receive udenafil or placebo for six months (Figure 1).  This study is 
supported by the National Heart, Lung, and Blood Institute (NHLBI)-funded PHN in cooperation 
with the sponsor, Mezzion Pharma Co. Ltd under a Special Protocol Assessment through the 
Food and Drug Administration.  We engaged with patient advocacy groups to help us 
understand potential barriers to recruitment as we prepared the protocol and recruitment 
materials.  Thirty clinical centers throughout the United States, Canada, and the Republic of 
Korea are participating.  A safety extension trial, the FUEL Open-Label Extension Trial (FUEL 
OLE) offers the opportunity for all FUEL subjects (regardless of their initial randomization 
assignment) to obtain open-label udenafil for an additional 12 months following completion of 
FUEL (Figure 2).  The primary purpose of FUEL OLE is to collect additional safety data on the 
use of udenafil in at least 300 adolescents with Fontan physiology.  Clinical efficacy parameters 
are also being re-evaluated at the conclusion of FUEL OLE to evaluate the durability of any 
changes noted in FUEL.  Funding for this project was provided by the National Heart, Lung, and 
Blood Institute and by Mezzion Pharma Co. Ltd. (Seoul, Republic of Korea).  The authors are 
solely responsible for the design and conduct of this study, all study analyses, the drafting and 
editing of the paper, and its final contents.  The clinicaltrials.gov reference numbers for FUEL 
and FUEL OLE are NCT0274115 and NCT03013751 respectively. 
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Rationale for FUEL and FUEL OLE 
Despite the rationale and potential efficacy signals that PDE-5 inhibitors may improve Fontan 
physiology, there has not been a clinical trial adequately powered to definitively answer the 
question of medication efficacy. We proposed to test the long-acting PDE-5 inhibitor, udenafil, 
as a therapeutic agent to improve VO2 max in adolescent subjects with Fontan physiology.  This 
multi-center, randomized, placebo-controlled clinical trial compares outcomes in those with 
Fontan physiology treated with six months of udenafil (87.5 mg twice daily) to those treated with 
placebo.  Given the progressive decline of VO2 max in those with the Fontan circulation, the 
identification of a treatment that is safe and that can slow this decline could alter the 
fundamental trajectory of those who have undergone the Fontan operation.  The primary aim of 
FUEL is to evaluate the effect of six months of treatment with udenafil (87.5 mg, twice daily) on 
exercise capacity in adolescents with Fontan physiology.  Secondary aims include assessing 
the effect of udenafil on echocardiographic measures of ventricular performance, on vascular 
function, on biomarkers of heart failure, and on functional health status.  Safety will be assessed 
in the FUEL trial and as the primary outcome of FUEL OLE. 
 
Among PDE-5 inhibitors, udenafil is the only medication to have undergone phase I/II testing in 
patients with Fontan physiology(37).  This trial, conducted in the PHN (NCT02201342), tested 
five different dosing strategies in cohorts of six subjects each.  Once-daily and twice-daily 
dosing strategies were both studied at increasing dosing strengths.  No drug-related serious 
adverse events were observed at any of the dosing regimens, and the 87.5 mg twice-daily 
regimen achieved the highest average serum concentrations of both udenafil and of its active 
metabolite.  This dosing regimen was also associated with an improvement in the myocardial 
performance index, a marker of possible clinical efficacy.  The results of the phase I/II trial led to 
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the selection of the udenafil dosing regimen of 87.5 mg twice daily for this phase III clinical 
efficacy trial.   
 
Patient selection 
Inclusion and exclusion criteria are listed in Table 1.  The decision to restrict the population to 
those older than 12 years of age and 132 cm or taller is based on the minimum size 
requirements needed to complete exercise testing, the primary outcome for this trial.  In an 
effort to focus solely on the impact of udenafil on Fontan physiology, subjects with severe 
ventricular dysfunction, severe atrioventricular valve regurgitation, or those who are aerobically 
deconditioned beyond what would be expected solely on the basis of Fontan physiology are 
excluded from participation.  This translates into excluding those with a recent history of a 
maximal VO2 below 50% predicted for age and gender.  Below this threshold there is concern 
that co-morbidities outside of the inherent limitations of Fontan physiology could overwhelm the 
potential impact of udenafil thereby blunting the ability to discern a meaningful effect.  To keep 
the mg/kg dose distribution within a relatively narrow range, inclusion is limited to those with a 
weight of 40 kg or greater, the minimal weight for an adult.  All subjects who complete the FUEL 
protocol are eligible for enrollment in FUEL OLE.  If fewer than 300 subjects choose to enroll in 
the open-label extension, the study will be opened to de novo Fontan patients who meet the 
eligibility criteria but did not participate in FUEL.  
 
FUEL randomization and stratification 
Eligible patients are randomly assigned to one of two treatment groups: udenafil or placebo.  A 
stratified randomization scheme is being employed with randomly permuted blocks of varying 
sizes.  Randomization assignments are generated by a web-based system at the data-
coordinating center after confirmation of trial eligibility. Stratification is based on ventricular 
morphology - single left ventricle vs. single right or mixed.  There is no pre-determined number 
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in each morphological stratum, rather ventricular morphologies are divided evenly between 
those receiving placebo and those receiving udenafil.  The rationale for this stratification is 
based on the results of the previous PHN Fontan cross-sectional studies (4,39). In these 
studies, there was a weak but significant difference in certain resting echocardiographic and 
exercise variables based on the morphology of the single ventricle. In addition, preliminary data 
on PDE-5 inhibitors suggest a difference in exercise performance based on morphology (23). 
 
Drug initiation 
Subjects undergo a blood draw to quantify hepatic and renal function, as well as a baseline 
exercise test prior to the first dose.  All female study participants must have a negative urine or 
serum pregnancy test before participating in exercise testing or receiving study drug.  
Participants who meet inclusion criteria and achieve a maximal effort on the exercise test 
(respiratory exchange ratio >1.10) will receive their first dose of study drug.  Participants who 
are unable to achieve a maximal effort on exercise testing, but who otherwise qualify for 
inclusion, are offered the opportunity to repeat the test one time within 2 weeks of the initial 
exercise test.  If the participant achieves a maximal effort on this second test, they will be 
eligible for randomization.  As a safety measure, if a participant demonstrates a fall in systolic 
blood pressure by 20 mmHg from the resting pre-exercise value, a fall in blood pressure below 
the 5th percentile for age (calculated by 2 x age in years + 65) at maximal exercise, or if the 
exercise test is terminated for arrhythmias or symptoms, the participant is not eligible for 
randomization. 
 
After satisfactory completion of the exercise test, participants are eligible for randomization and 
study drug initiation at any time within seven days of the baseline testing. The first dose is 
administered in the presence of study personnel.  At approximately two hours after the first 
dose, participants are asked to perform a self-limited 6-minute walk.  As with the exercise test, if 
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there is a significant drop in blood pressure during the 6-minute walk, participants are excluded 
from receiving any further study drug.  
 
Subjects who consent to FUEL OLE upon completion of FUEL are able to use study measures 
collected at the 6-month FUEL visit as baseline measures for FUEL OLE, provided the study 
drug initiation visit is conducted within a reasonable time period (<2 months). Drug initiation 
procedures for FUEL OLE mirror those for FUEL. The baseline visit for de novo FUEL OLE 
subjects mirrors the baseline screening and drug initiation visit for FUEL.  
 
Trial outcomes 
Outcomes include measures obtained through exercise testing, echocardiography, and 
assessment of vascular function, as well as serum levels of brain type natriuretic peptide.  
Participants also complete assessments of functional health status.  Safety data are collected 
during both FUEL and FUEL OLE when reported by participants and during prescribed phone 
calls between participants and study personnel.  All testing performed at end-of-study will be 
compared to baseline testing.  A complete list of outcome variables can be found in Table 2.   
 
Exercise 
The primary outcome for the FUEL trial is the change in VO2 max from baseline to 26-week 
testing for those who receive study drug compared to those who receive placebo.  VO2 max is 
the exercise measure that has been most closely correlated with morbidity and mortality in the 
Fontan population, and a positive change in VO2 max would suggest an improvement in overall 
physiology.  Measurements of VO2 max occur locally at each study site using a standardized 
cycle ergometer ramp protocol as has been previously described in children and adolescents 
with Fontan physiology(38).  Secondary exercise outcomes include additional measures of 
exercise performance at maximal effort and at the ventilatory anaerobic threshold. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 11 
 
Echocardiography  
Echocardiographic images are obtained at each site according to a standardized protocol.  
These images are sent to a core lab with specific expertise in functional measurements.  The 
primary echocardiographic endpoint is the myocardial performance index, a measure of global 
ventricular function that has been noted to improve with use of PDE-5 inhibitors in the Fontan 
population in previous studies(26,37).  Secondary endpoints include tricuspid / mitral annular 
planar systolic excursion, a measure that has been linked to exercise performance(39), and the 
systolic to diastolic ratio, a measure that has been linked to ventricular end-diastolic pressure 
and to mortality in adults with Fontan physiology(40-42).  Additional secondary endpoints will 
include estimates of cardiac output and measures of ventricular function obtained through 
Doppler tissue imaging techniques.  
 
Vascular function 
Peripheral vascular function is assessed using the EndoPAT® device.  This device measures 
blood flow to the index finger before and after a period of induced distal limb ischemia, with 
control data measured from the contralateral (non-ischemic) limb.  Ischemia is accomplished 
using a brachial blood pressure cuff inflated beyond the systolic blood pressure for a period of 
five minutes.  Data from these tests are collected at each site and sent to a core lab for 
interpretation.  The primary outcome for vascular function is the log-transformed reactive 
hyperemia index, which is obtained by comparing blood flow before and after limb ischemia, 
adjusted for the control arm, and has been shown to correlate with functional capacity and 
quality of life(8).  An additional outcome measure of vascular function is the augmentation index, 
which is a measure of arterial stiffness.   
 
Serum brain-type natriuretic peptide 
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Blood samples for the measurement of serum brain-type natriuretic peptide (BNP) are obtained 
at the baseline visit and at the 26-week visit for FUEL and the 52-week visit for FUEL OLE.  
These samples are sent to a core lab to determine serum BNP levels. 
 
Functional health status 
Functional health status is assessed using standardized instruments including the Pediatric 
Quality of Life Inventory (PedsQL) and the Pediatric Cardiac Quality of Life Inventory (PCQLI).  
The PedsQL and the PCQLI are administered at the baseline visit and at the 26-week visit for 
FUEL and the 52-week visit for FUEL OLE.  Subsets of the PedsQL are also evaluated 
including the physical functioning score, the psychosocial functioning score, and the cardiac-
specific quality of life score. 
 
Masking 
The study medication and the placebo are identical in appearance.  Although the study is 
double-blinded, it is possible that some FUEL subjects may suspect they have been randomized 
to udenafil based on the side-effect profile.  However, the randomization assignment is only 
seen by the statistician at the data coordinating center and is not available to the family, subject, 
study coordinator, investigators, or personnel administering the baseline or end-of-study testing.  
The exercise testing laboratories and the echocardiography and vascular core labs are likewise 
masked to group assignment.  All participants and sites will remain masked to treatment group 
assignment until after all trial data are analyzed.  Unmasking may occur when deemed 
necessary by the principal investigator, sponsor, or medical monitor in the event of a serious 
adverse event with a potential relationship to study drug.  
 
Study measurements and subject follow-up 
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During the FUEL trial, drug accountability is assessed and measurements of blood pressure and 
heart rate are repeated at visits during week 2 and week 13.  For female subjects, a urine 
pregnancy test is also repeated during these visits.  Medication exposure is reviewed and 
adverse events are assessed weekly for four weeks and then monthly through the end of the 6-
month trial.  Adverse events are also assessed 24 hours following drug initiation.  For subjects 
participating in FUEL OLE, the procedures for drug accountability are identical to those for 
FUEL, but the monthly assessment of adverse events continues through the end of the study.  
Adverse events are evaluated at one and three months after the last dose of study drug that an 
individual participant receives.   
 
Statistical considerations 
Primary outcome 
A sample size of 200 subjects per arm was chosen to allow for 90% power to detect a mean 
treatment difference in change from baseline to 26-week testing in VO2 max of 10% while taking 
into account the assumptions listed below.  These assumptions were based on historical data 
and were purposefully conservative to mitigate the risk of completing the study with inadequate 
power(3,4).  Assumptions include: 
 Baseline standard deviation of VO2 max of 6.25 ml/kg/min 
 Correlation between baseline and 26-week testing within an individual of 0.33 
 Drop-out and incomplete testing rate of 10% 
 Failure to generate a maximal exercise test at the 26-week visit in 15% of subjects 
With an anticipated population mean VO2 max of 28 mL/kg/min, this sample size would allow us 
to detect an improvement of 2.8 mL/kg/min in the udenafil group compared to zero change in 
the control group, assuming a Type 1 error of 0.05.   
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The primary analysis at study end will use an intention-to-treat model.  The change in VO2 max 
will be calculated and analysis of covariance will be used to determine whether the mean 
change in maximal oxygen consumption from baseline to 26-weeks is significantly different 
between the udenafil and placebo groups after adjusting for baseline values of VO2 and 
ventricular morphology.  Secondary analyses will be performed for pre-specified subgroups 
including ventricular morphology (left versus right or mixed).  The subgroup analyses are 
exploratory since the trial isn’t powered to detect treatment differences within subgroups.   
 
 
Secondary outcomes 
Secondary exercise performance outcomes, most echocardiographic parameters, and vascular 
function measures are continuous data points and will be analyzed in the manner described for 
the primary outcome.  If measures are highly skewed, then regression modeling will be 
conducted on a suitably transformed outcome, where possible, to achieve a distribution that is 
closer to normality (e.g., log-transformed BNP instead of raw values).  Any echocardiographic 
indices that are not continuous (e.g. severity of atrioventricular valve regurgitation) will be 
assessed using a Cochran-Mantel-Haenszel test with ventricular morphology as the 
stratification factor.  Treatment group differences for endpoints associated with quality of life 
instruments will be assessed with Friedman’s test with ventricular morphology as the 
stratification factor. 
 
Interim analysis / safety monitoring 
There are no efficacy interim analyses planned for this study.  The PHN’s Data and Safety 
Monitoring Board (DSMB), established by NHLBI, routinely reviews study data at set intervals 
throughout the study period.  The DSMB has the authority to recommend stopping the trial for 
safety concerns.  Given the short duration of this clinical trial, there will not be an opportunity to 
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review the data for futility.  An independent medical monitor reviews all adverse events on a 
regular basis, including relationship to study drug. 
 
Discussion 
Choice of primary outcome 
Studying the effect of any intervention in the Fontan population is difficult given the absence of 
readily measured, reliable and reproducible endpoints.  This lack of clear endpoints for the study 
of Fontan physiology is primarily related to the small numbers of patients with this unique 
physiology and the slow rate of attrition (heart failure, death, and transplant), both in absolute 
terms and relative to other populations, such as adults with heart failure.  The PHN Fontan 
Cross-Sectional and Longitudinal Studies were the largest attempts to characterize this group, 
but included several hundred rather than the several thousand subjects that might be included 
in studies of other forms of heart disease(3,4). 
 
Given the difficulty with hard endpoints, exercise capacity is frequently used as a surrogate 
outcome in those with CHD.  As noted, VO2 max has been shown to be a consistent and 
sensitive marker of deteriorating function, onset of symptoms of heart failure, and increasing risk 
for death in the population with the Fontan procedure(3,5-7,17-20).  Although an alteration of 
the decline in exercise capacity over time was considered as the primary outcome, 
contemporary data from the PHN suggested that the rate of decline in the modern era might be 
more gradual than that reported for older cohorts, which would make it difficult to detect a 
change in the slope of decline within a reasonable study period(3).  Given that limitation, a 
positive change in exercise capacity was determined to be a more practical endpoint. 
 
Choice of trial duration  
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Although the acute benefit of PDE5 inhibitors and pulmonary vasodilators on Fontan physiology 
has been demonstrated by a number of prior studies(23-31), the important question is whether 
these benefits hold up over a longer period of time and whether they might be associated with a 
forestalling of the onset of the development of symptoms associated with “Fontan-failure.”  
Given the rate of the decline of exercise performance in those with Fontan physiology, an ideal 
study design would involve randomization and continuation of the study over many years.  
However, such a design would make recruitment and retention a potentially insurmountable 
challenge.  The decision to choose a six-month study period was based on an attempt to 
balance the challenge of recruiting into a long-term study with the goal of observing the impact 
of udenafil over a meaningful period of time.  The six-month time period should allow for a 
reasonable assessment of the impact of udenafil on exercise performance beyond the acute 
effect and for a “real-life” assessment of medication adherence and of the side effect profile.    
 
Importance of Partnering with Patient Advocacy Groups 
The FUEL trial is unique in scope and size in congenital cardiology and the success of the trial 
depends critically on the enthusiasm of patients and their families.  By partnering with patient 
advocacy groups, we were better able to understand the barriers to participation created by the 
time consuming nature of the study procedures.  This led to the creation of a travel fund to 
support families coming from a distance, and led to the distribution of portable devices to help 
provide reminders to assist with medication adherence.  Using family feedback, we were also 
able to design subject compensation in a manner commensurate with the time and effort 
expended and to modify the protocol to try to minimize the disruption to the lives of the 
adolescent participants.  In addition, the partnership with advocacy groups has facilitated a 
coordinated dissemination of information about the trial to potential participants who are 
followed by sites that are not participating in this trial.  We were able to present a live webinar in 
which we reviewed the rationale and outline of the trial, and were then able to provide a link to 
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the webinar to those potential participants who were not able to view the presentation as it 
occurred.  
 
Importance of the clinical trial and timeline for completion 
Since the initial description of the Fontan operation there have been numerous innovations that 
have allowed for improved perioperative and long-term survival for those born with single 
ventricle CHD(43-46).  However, while early survival has improved, progressive morbidity is still 
pervasive(47,48).  The elevated central venous pressure and low cardiac output that are 
hallmarks of the Fontan circulation create a unique form of chronic heart failure for which no 
specific treatment exists.  If udenafil is confirmed to be a safe and well-tolerated chronic 
medication that improves exercise performance in Fontan physiology, it would have 
considerable potential to improve other outcomes for the growing population of children, 
adolescents, and adults with palliated single ventricle CHD.  As of manuscript submission, 367 
participants have been randomized at 30 sites and it is expected that recruitment will be 
completed by the end of June of 2018.  This timeline would allow for the presentation of the 
primary results in the first quarter of 2019. 
 
Limitations 
The relatively small number of subjects with this rare condition will make it hard to detect 
improvements in the primary outcome that are smaller than anticipated, as well as subtle 
improvements in the secondary exercise and imaging outcomes.  Although the trial is powered 
robustly for the primary outcome, it is limited in its enrollment goal by the reality that single 
ventricle heart disease is a rare pediatric disease.  In addition, while the trial will have six 
months of safety data from FUEL and an additional 12 months of data from FUEL OLE, that 
amount of data is likely insufficient to adequately assess the long-term safety of udenafil.  If 
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udenafil is to be used extensively in those with Fontan physiology, on-going surveillance will be 
necessary to ensure long-term safety across the population. 
 
Conclusions 
While the Fontan operation has been life-saving for generations of children born with single 
ventricle CHD, there is a clear need to develop therapies aimed at improving this unique 
circulation.  Medications that target PVR may be uniquely suited to improve Fontan physiology 
by lowering central venous pressure and increasing cardiac output.  Among pulmonary 
vasodilators, PDE-5 inhibitors have a strong track record of safety and are currently the front-
line therapy for children with pulmonary arterial hypertension.  Udenafil is unique among PDE-5 
inhibitors in that it has been studied in a phase I/II trial in adolescents who have undergone the 
Fontan operation.  Given the theoretical benefit of udenafil in those with Fontan physiology, we 
have the opportunity to answer the question of clinical utility in the setting of relative equipoise 
among pediatric cardiologists, Fontan patients, and their families.  The FUEL and FUEL OLE 
trials have the potential to make a substantial contribution to the care of those born with single 
ventricle heart disease who have survived beyond the Fontan operation. 
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Table 1: FUEL Inclusion and Exclusion Criteria 
Inclusion Criteria 
1 Males and females with Fontan physiology 12 – <19 years of age at enrollment 
2 Participant consent or parental/guardian consent with participant assent 
3 Participant fluent in English, Spanish, or Korean 
Exclusion Criteria 
1 Weight <40 kg 
2 Height <132 cm 
3 Hospitalization for acute decompensated heart failure within the last 12 months 
4 Current intravenous inotropic drugs 
5 Undergoing evaluation for heart transplantation or listed for transplantation 
6 Diagnosis of active protein losing enteropathy or plastic bronchitis within the last 3 
years, or a history of liver cirrhosis 
7 Known Fontan baffle obstruction, branch pulmonary artery stenosis, or pulmonary 
vein stenosis resulting in a mean gradient of >4 mmHg between the regions 
proximal and distal to the obstruction as measured by either catheterization or 
echocardiography, obtained prior to screening for the trial 
8 Single lung physiology with greater than 80% flow to one lung 
9 VO2 max less than 50% of predicted for age and gender at enrollment 
10 Severe ventricular dysfunction assessed qualitatively by clinical echocardiography 
within six months prior to enrollment 
11 Severe valve regurgitation, ventricular outflow obstruction, or aortic arch 
obstruction assessed by clinical echocardiography within six months prior to 
enrollment 
12 Significant renal (serum creatinine >2.0), hepatic (serum AST and/or ALT >3 
times upper limit of normal), gastrointestinal or biliary disorders that could impair 
absorption, metabolism or excretion of orally administered medications, based on 
laboratory assessment six weeks prior to screening for the trial 
13 Inability to complete exercise testing at baseline screening 
14 History of PDE-5 inhibitor use within 3 months before study onset 
15 History of any other medication for treatment of pulmonary hypertension within 3 
months before study onset 
16 Known intolerance to oral udenafil 
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17 Frequent use of medications or other substances that inhibit or induce CYP3A4 
18 Current use of alpha-blockers or nitrates 
19 Ongoing or planned participation in another research protocol that would either 
prevent successful completion of planned study testing or invalidate its results 
20 Non-cardiac medical, psychiatric, and/or social disorder that would prevent 
successful completion of planned study testing or would invalidate its results 
21 Cardiac care, ongoing or planned, at a non-study center that would impede study 
completion 
22 For females: pregnancy at the time of screening, pregnancy planned before study 
completion, or refusal to use an acceptable method of contraception for study 
duration if sexually active 
23 Inability to abstain from or limit intake of grapefruit juice during the duration of the 
trial 
24 Refusal to provide written informed consent/assent 
25 In the opinion of the primary care physician, the subject is likely to be non-
compliant with the study protocol 
ALT – alanine aminotransferase; AST – aspartate aminotransferase; PDE-5 – 
phosphodiesterase type 5; CYP3A4 – cytochrome P450 3A4; VO2 max – maximal oxygen 
consumption 
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Table 2: Outcome Measures 
Cardiopulmonary Exercise Testing 
Primary outcome Change in VO2 max from baseline to six 
months  
Secondary outcomes  Six-month change in: 
 Minute oxygen consumption at the VAT  
 Respiratory rate and minute ventilation 
at peak exercise 
 Ventilatory equivalents of carbon 
dioxide at the VAT  
 Maximal work rate 
 Work rate at the VAT 
Echocardiography 
Primary outcome Change in MPI from baseline to six months as 
determined by velocities obtained from blood 
pool Doppler assessment 
Secondary outcomes  Six-month change in: 
 Ventricular cavity size, eccentricity and 
mass 
 Two-dimensional, Doppler and tissue 
Doppler based estimates of ventricular 
systolic and diastolic function  
 Qualitative and quantitative estimates 
of AV valve insufficiency 
Vascular Function 
Primary outcome Change in EndoPAT® derived log-transformed 
reactive hyperemia index from baseline to six 
months 
Serum Brain-Type Natriuretic Peptide 
Primary outcome Change in the measured level of serum brain-
type natriuretic peptide from baseline to six 
months 
Functional Health Status 
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Primary outcome The change in functional health status from 
baseline to six months as measured by the full 
scale PedsQL assessment tool 
Secondary outcomes  Six-month change in: 
 PedsQL Physical Functioning score 
 PedsQL Psychosocial Functioning 
score 
 PedsQL Cardiac-Specific Quality of 
Life score 
 Pediatric Cardiac Quality of Life 
Inventory score 
VO2 max – maximal oxygen consumption; VAT – ventilatory anaerobic threshold; MPI – 
myocardial performance index; AV – atrioventricular; PedsQL – Pediatric Quality of Life 
Inventory 
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Figure 1 
 
 
 
 
 
 
  
FUEL Schema 
Males and Females 12-under 19 yrs. 
with Fontan Physiology 
NO CONSENT 
Baseline In-Person Visit/Day 0 
CONSENT 
INELIGIBLE 
Eligible – Max Effort Achieved on exercise test 
Stratum 1 
LV 
Morphology 
Stratum 2 
Mixed or RV 
Morphology 
Blinded 
Udenafil 
Blinded 
Placebo 
Vital signs, administer study drug, 6 minute 
walk, vital signs, PK sample, questionnaires 
 
Max effort not achieved on  
up to two exercise test attempts 
OR 
If ↓ systolic BP by 20 mmHg from pre-
exercise value OR if systolic BP ↓ below 
5th percentile*, OR 
Symptoms or arrhythmias resulting  
in the termination of exercise test 
*calculated by 2 x age in years + 65 
 
Telephone Calls  
Day 1, Weeks 1, 2, 3, 4, 8, 13, 17, 21 
 
Review drug adherence (Morisky scale) and 
interval adverse events and update 
concomitant medications  
Final Study Visit Week 26 
 
End of Study Testing: EndoPAT, 
echocardiogram, exercise test, 
blood work, pregnancy test 
(females only) 
 
Final review of drug adherence and 
interval adverse events and update 
concomitant medications 
Randomization 
Baseline Testing: EndoPAT, echocardiogram, exercise 
test, blood work, pregnancy test (females only) 
If systolic BP ↓ > 20 mmHg from pre-walk OR 
if systolic BP ↓ below 5th percentile*, subject 
will receive no further study drug and will be 
followed for 90 days for AE’s. 
*calculated by 2 x age in years + 65 
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Figure 2 
 
 
CONSENT
Baseline In-Person Visit/Day 0
NO CONSENT
FUEL Participant New FUEL OLE Participant
Resting vital signs, dispense one dose udenafil 
(87.5 mg), 6 minute walk, vital signs, PK sample, 
questionnaires
Max effort not achieved on  up to two 
exercise test attempts OR
If ↓ systolic BP by 20 mmHg from pre-
exercise value OR if systolic BP ↓ 
below 5th percentile*, OR
Symptoms or arrhythmias resulting 
in the termination of exercise test
*calculated by 2 x age in years + 65
INELIGIBLE: Follow for 30 days 
for safety
Telephone Calls
Day 1, Weeks 1, 2, 3, 4, 8, 13, 17, 21, 30, 34, 39, 43, 47
Review drug adherence (Morisky scale) and interval 
adverse events and update concomitant medications
Final Study Visit Week 52
End of Study Testing: 
EndoPAT, echocardiogram, 
exercise test, blood work, 
pregnancy test (females only)
Final review of drug adherence 
and interval adverse events 
and update concomitant 
medications
Max Effort 
Achieved on EST
Baseline Testing: EndoPAT, 
echocardiogram, exercise test, blood work, 
pregnancy test (females only)
Systolic BP ↓ > 20 mmHg from 
pre-walk OR if systolic BP ↓ 
below 5th percentile*
No ¯ in systolic BP from 
pre-walk BP
INELIGIBLE: Follow for 90 days 
per FUEL protocol
FUEL OLE Schema
Males and Females 12-under 19 yrs. 
with Fontan Physiology
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